



U.S. Department of Defense issued a 'COVID-19 Research' contract 3 Months before COVID-19 was known to officially exist

Description

 Print  PDF  Email

The discovery of a contract awarded by the U.S. Department of Defense to Labyrinth Global Health for “COVID-19 Research” in November 2019 has raised questions about the Government’s knowledge of the novel coronavirus.

The contract was part of a larger project for a “Biological threat reduction program in Ukraine,” suggesting that the U.S. Government was at the very least aware of the virus before it spread through Wuhan, China in December 2019, and before it was officially named Covid-19 by the World Health Organization in February 2020.

These findings raise concerns about the Government’s handling of the pandemic and the potential for a cover-up.

The U.S. Government’s “USA Spending” website reveals that it had spent a staggering \$4.04 trillion “in response to COVID-19”. A deeper look at the website’s “Award Search” feature uncovers a contract awarded by the Department of Defense to Black & Veatch Special Projects Corp. for “Professional, Scientific, and Technical Services” on September 20, 2012.

A closer examination of the contract’s “Sub-Awards” tab reveals 115 transactions with recipients and brief descriptions, the majority of which are mundane items like “laboratory equipment for Kyiv” and “office furniture for Kyiv.”

Total Count of Sub-Award Transactions: 115 Total Amount of Sub-Awards: \$107.15 million Percent of Prime Award Obligated Amount: 136.9%

Sub-Award ID	Recipient Name	Action Date	Amount	Description
19-6187	SWA-STAL, TOV	10/21/2019	\$248,263	LABORATORY FURNITURE FOR KYIV AND ODESA ILDS
19-6188	UKRAINIAN ENERGY CONSULTING GROUP, TOV	09/01/2019	\$81,699	TESTING OF EQUIPMENT IN LABS
19-6189	BIOMEX LAB, LLC	06/15/2019	\$43,708	UP-4 OVS LABORATORY SUPPLIES
19-6190	SKOI TRICHEL HOLDING LTD, TOV	06/12/2019	\$174,081	TRAVEL
19-6177	ALT UKRAINA LTD, TOV	07/16/2019	\$37,806	LABORATORY EQUIPMENT FOR KYIV AND ODESA ILDS
19-6176	BIOLABTOR LTD, TOV	07/05/2019	\$105,489	LABORATORY EQUIPMENT FOR KYIV AND ODESA ILDS
19-6174	UNILAB, TOV	07/05/2019	\$271,480	LABORATORY EQUIPMENT FOR KYIV AND ODESA ILDS
19-6174	UNILAB, TOV	07/05/2019	\$276,645	LAB EQUIPMENT AND SUPPLIES FOR KYIV AND ODESA ILDS
19-6175	SMART DEFENSE, TOV	07/09/2019	\$872,753	LABORATORY EQUIPMENT FOR KYIV AND ODESA ILDS
19-6172	AKTSIONERNA STRUKHONA KOMPANYI INKO UKRAINA ZHYTTYA, AT	05/06/2019	\$77,659	HEALTH INSURANCE

Click to enlarge

There is, however, among the 115 transactions listed in the “Sub-Awards” tab of a contract awarded by the U.S. Department of Defense to Black & Veatch Special Projects Corp. one transaction that stands out:

An award to Labyrinth Global Health INC for “SME Manuscript Documentation and COVID-19 Research.”

While it is not surprising to see an award for Covid-19 research during a pandemic, the fact that the contract was awarded on November 12, 2019, at least one month before the alleged emergence of the novel coronavirus and three months before it was officially named Covid-19, raises questions about the government’s knowledge of the virus.

Recipient Name	Action Date	Amount	Description
ARKHITEKTURNO-BUDIVELNA GRUPA PALATIUM, TOV	10/22/2019	\$75,235	OFFICE FURNITURE FOR KYIV AND ODESA ILDS
LABYRINTH GLOBAL HEALTH INC	11/12/2019	\$369,511	SME MANUSCRIPT DOCUMENTATION AND COVID 19 RESEARCH
LABYRINTH GLOBAL HEALTH INC	11/12/2019	\$50,000	TASK ORDER 1
BIOSAFE ENGINEERING, LLC	11/26/2019	\$795,995	TISSUE DIGESTERS FOR KYIV AND ODESA ILDS

[Source](#)

Furthermore, the contract was instructed to take place in Ukraine, as was the entire contract awarded to [Black & Veatch Special Projects Corp.](#) These findings suggest potential U.S. Government involvement in the creation and spread of the virus.

In September 2012, the Defense Threat Reduction Agency (DTRA) within the US Department of Defense awarded a contract to a global engineering, procurement, and construction company specializing in infrastructure development.

Agency Details		
Awarding Agency	Department of Defense (DOD)	
Awarding Sub-Agency	Defense Threat Reduction Agency	
Awarding Office	DEFENSE THREAT REDUCTION AGENCY	
Funding Agency	Department of Defense (DOD)	
Funding Sub-Agency	Defense Threat Reduction Agency	
Funding Office	DEFENSE THREAT REDUCTION AGENCY	

Parent Award Details		
Parent Award Unique Key	CONT_IDV_HDTRA108D0007_9700	
Parent Award ID (Parent PIID)	HDTRA108D0007	
Parent IDV Type	IDC	
Parent IDV Agency Name	Department of Defense	
Parent IDV Sub-Agency Name	Department of Defense	
Multiple Or Single Parent Award IDV	SINGLE AWARD	

Place Of Performance		
Address	UKRAINE -- UKRAINE	

Period Of Performance		
Start Date	09/20/2012	
End Date	10/13/2020	
Potential End Date	10/13/2020	

The contract was for a Biological threat reduction program in Ukraine, and concluded in October 2020. While the details are unclear, it is known that \$21.7 million of the \$116.6 million contract was spent on this program.

Award History

Transaction History

Sub-Awards 135

Federal Account Funding

Modification Number	Action Date	Amount	Action Type	Description
20	05/16/2018	-\$12,955,750	C: FUNDING ONLY ACTION	CRFP UKRAINE PROJECT (SCIENTIFIC ENGAGEMENT AND FACILITY UPGRADES)
21	05/31/2018	\$4,265,677	C: FUNDING ONLY ACTION	IGF-01-IGF MODIFICATION 21 IS TO INCREMENTALLY FUND THE CONTRACT AND CHANGE THE COR.
22	08/29/2018	\$158,808	C: FUNDING ONLY ACTION	CRFP UKRAINE (SCIENCE ENGAGEMENT AND RENOVATION OF LABS)
23	09/21/2018	\$21,796,196	B: SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE	BIOLOGICAL THREAT REDUCTION PROGRAM IN UKRAINE - SCIENCE ENGAGEMENT AND INCREASING LABORATORY CAPABILITY
24	03/31/2019	\$7,694,223	C: FUNDING ONLY ACTION	PRIO, TRAINING, RESEARCH, AND SUSTAINMENT
25	08/31/2019	-\$982,972	C: FUNDING ONLY ACTION	PRIO, TRAINING, RESEARCH, AND SUSTAINMENT
26	08/26/2019	\$2,194,196	C: FUNDING ONLY ACTION	PRIO, TRAINING, RESEARCH, AND SUSTAINMENT
27	09/20/2019	\$0	M: OTHER ADMINISTRATIVE ACTION	PRIO, TRAINING, RESEARCH, AND SUSTAINMENT
28	12/12/2019	\$0	C: FUNDING ONLY ACTION	PRIO, TRAINING, RESEARCH, AND SUSTAINMENT
29	03/11/2020	-\$3,808,000	E: EXERCISE AN OPTION	PRIO, TRAINING, RESEARCH, AND SUSTAINMENT

Source

It is puzzling why the DOD would contract a company specializing in infrastructure development for a biological threat reduction program.

Furthermore, it is intriguing that both the DOD and the contracting company subsequently paid Labyrinth Global Health INC to conduct COVID-19 research in Ukraine prior to the emergence of the novel coronavirus and before it was officially named Covid-19.

These events raise questions about the nature of the biological threat reduction program and its potential connection to the alleged COVID-19 pandemic. And the discovery of a contract awarded by the U.S. Department of Defense for Covid-19 research in November 2019 suggests that the U.S Government either knew the virus existed naturally or was involved in constructing it in a lab.

This theory is supported by evidence that the National Institute of Allergy & Infectious Diseases (NIAID) and Moderna had a coronavirus candidate in December 2019.

A [confidentiality agreement](#) reveals that NIAID and Moderna agreed to transfer “mRNA coronavirus vaccine candidates” to the University of North Carolina at Chapel Hill on December 12, 2019.

PUBLIC HEALTH SERVICE

MATERIAL TRANSFER AGREEMENT

This Material Transfer Agreement ("MTA") has been adopted for use by the National Institutes of Health, the Food and Drug Administration and the Centers for Disease Control and Prevention, collectively referred to herein as the Public Health Service ("PHS") in all transfers of research material (Research Material) whether PHS is identified below as its Provider or Recipient.

Providers: *National Institute of Allergy and Infectious Diseases, National Institutes of Health ("NIAID")*
ModernaTX, Inc ("Moderna")

Recipient: The University of North Carolina at Chapel Hill

1. Provider agrees to transfer to Recipient's Investigator the following Research Material:

mRNA coronavirus vaccine candidates developed and jointly-owned by NIAID and Moderna.

Found on page 105 of the agreement

[Source](#)

The material transfer agreement was signed the December 12th 2019 by Ralph Baric, PhD, at the University of North Carolina at Chapel Hill, and then signed by Jacqueline Quay, Director of Licensing and Innovation Support at the University of North Carolina on December 16th 2019.

MATERIAL TRANSFER AGREEMENT SIGNATURE PAGE

FOR RECIPIENT:

Recipient's Investigator




Ralph Baric, PhD
Professor

Date: 12/12/2019

Mailing Address for Materials:

Attention: Dr. Rachel Graham, Department of
Epidemiology, University of North Carolina at
Chapel Hill, 135 Dauer Drive, 2101 McGavran-
Greenberg Hall, CB #7435, Chapel Hill, NC 27599-
7435

Duly Authorized



Jacqueline Quay
Director, Licensing & Innovation Support, OTC

Date: 12/16/19

Mailing Address for Notices:


The University of North Carolina at Chapel Hill
Office of Technology Commercialization
109 Church Street, Chapel Hill, NC 27516
Tel: 919-966-3929 Fax: 919-962-0646

Recipient signatories found on page 107

Source

The agreement was also signed by two representatives of the NIAID, one of whom was Amy F. Petrik PhD, a technology transfer specialist who signed the agreement on December 12th 2019 at 8:05 am. The other signatory was Barney Graham MD PhD, an investigator for the NIAID, however, this signature was not dated.

Tel: 919-966-3895 Fax: _____

FOR PROVIDERS:*NIAID's Investigator*


 Barney Graham, MD, PhD

Date: _____

Duly Authorized

Amy F.

Petrík-S

Digitally signed by Amy
F. Petrík-SDate: 2019.12.12
08:05:22 -05'00'

Amy Petrík, PhD

Technology Transfer Specialist, TTPO, NIAID

Date: _____

Mailing Address for Notices:

Technology Transfer and Intellectual Property Office
 National Institute of Allergy and Infectious Diseases
 Department of Health and Human Services
 Suite 6D, MSC 9804
 5601 Fishers Lane
 Rockville, MD 20852
 Tel: 301/496-2644 Fax: 240-627-3117

NIAID signatories found on page 107[Source](#)

The final signatories on the agreement were Sunny Himansu, Moderna's Investigator, and Shaun Ryan, Moderna's Deputy General Counsel. Both signatures were made on December 17th 2019.

Moderna's Investigator


 Sunny Himansu, PhD

Date: 12/17/2019

*Duly Authorized**Shaun Ryan*

Shaun Ryan

Deputy General Counsel

Date: 12/17/19

Mailing Address for Notices:

ModernaTX, Inc.
 200 Technology Square
 Cambridge, MA 20139
 Attn: General Counsel

Moderna signatories found on page 108[Source](#)

All of these signatures were made prior to the general public having any knowledge of the alleged emergence of the novel coronavirus.

It wasn't until December 31st 2019 that the World Health Organisation (WHO) became aware of an alleged cluster of viral pneumonia cases in Wuhan, China.

But even at this point, they had not determined that an alleged new coronavirus was to blame, instead stating the pneumonia was of "unknown cause".

INFORMATION

31 Dec 2019

WHO's Country Office in the People's Republic of China picked up a media statement by the Wuhan Municipal Health Commission from their website on cases of 'viral pneumonia' in Wuhan, People's Republic of China.

The Country Office notified the International Health Regulations (IHR) focal point in the WHO Western Pacific Regional Office about the Wuhan Municipal Health Commission media statement of the cases and provided a translation of it.

WHO's Epidemic Intelligence from Open Sources (EIOS) platform also picked up a media report on ProMED (a programme of the International Society for Infectious Diseases) about the same cluster of cases of "pneumonia of unknown cause", in Wuhan.

Several health authorities from around the world contacted WHO seeking additional information.

It was not until January 9th 2020 that the [WHO reported](#) Chinese authorities had determined the outbreak was due to a novel coronavirus which later became known as SARS-CoV-2 with the alleged resultant disease dubbed COVID-19.

So why was an mRNA coronavirus vaccine candidate developed by Moderna being transferred to the University of North Carolina on December 12th 2019?

The same Moderna that have had an mRNA coronavirus vaccine authorised for emergency use only in both the United Kingdom and United States to allegedly combat Covid-19.

What did Moderna know that we didn't? In 2019 there was not any singular coronavirus posing a threat to humanity which would warrant a vaccine.

As the world tries to move on from the alleged Covid-19 pandemic, there are many questions that remain unanswered.

What caused the alleged outbreak? Was it naturally occurring, or was it the result of human intervention?

The discovery of a contract awarded by the U.S. Department of Defense for Covid-19 research in November 2019 suggests that the U.S Government knows the answer to those questions.

Category

1. Army-Wars-Conflict Zones-Military Tech.
2. Crime-Justice-Terrorism-Corruption
3. Health-Wellness-Healing-Nutrition & Fitness
4. Main
5. NWO-Deep State-Dictatorship-Tyrrany

Date Created

12/20/2022